Key clinical point: The oral drug imidafenacin shows promise in a phase 2 trial in chronic obstructive pulmonary disease (COPD).
Major finding: In patients who took the drug, maximum change in FEV1 significantly improved over 24 hours vs. placebo.
Study details: Multicenter, randomized, double-blind 3×3 crossover Phase 2 trial of a single dose of oral imidafenacin (0.1 mg or 0.2 mg) vs. placebo in 27 male patients with COPD.
Disclosures: Ono Pharmaceutical funded the study. The authors report various disclosures.
Machida K et al. Int J Chron Obstruct Pulmon Dis. 2019;14:2175–84.